BioCentury | Apr 28, 2020
Finance

Merck’s adjusted revenue guidance shows product mix matters during COVID-19

Merck’s heavy reliance on hospital-administered products, vaccines and animal health has left it more exposed than its pharma peers to the commercial impacts of the COVID-19 pandemic. The company cut its 2020 revenue guidance by...
BioCentury | Feb 6, 2020
Deals

Beyond Keytruda: How Merck envisions innovation and growth after a spinout

As Merck becomes the latest large pharma to split in two, separating its key growth drivers and innovative programs from its slower-growing businesses, the slimmed-down innovative company will rely on the fruits of recent and...
BioCentury | Jan 4, 2016
Finance

Big band swing

Many investors treated biotech's dismal 3Q15 as a buying opportunity, and the effects were apparent in 4Q15. All of the market cap bands showed positive gains save for the microcaps. Big biotechs led the charge...
BC Week In Review | Dec 21, 2015
Clinical News

Bridion sugammadex regulatory update

FDA approved Bridion sugammadex from Merck to reverse the effects of neuromuscular blockade induced by muscle relaxants rocuronium or vecuronium in adults undergoing surgery. Merck plans to launch the cyclodextrin derivative next month, at which...
BC Extra | Dec 15, 2015
Company News

FDA approves Merck's Bridion

FDA approved Bridion sugammadex from Merck & Co. Inc. (NYSE:MRK) to reverse the effects of neuromuscular blockade induced by muscle relaxants rocuronium or vecuronium. Merck spokesperson Pamela Eisele said the company plans to launch the...
BC Extra | Nov 5, 2015
Clinical News

FDA reviewers accept sugammadex data

In sugammadex from Merck & Co. Inc. (NYSE:MRK), agency reviewers said the company has resolved the agency's concerns over the integrity of hypersensitivity data and asked panelists to vote on whether there are sufficient data...
BioCentury | Oct 5, 2015
Finance

Event planner

For investors who are not inclined to sit it out until the volatility abates, the fourth quarter is bursting with late-stage catalysts. There are no fewer than 17 PDUFA dates on the calendar before year...
BC Week In Review | Sep 28, 2015
Clinical News

Bridion sugammadex regulatory update

FDA’s Anesthetic and Analgesic Drug Products Advisory Committee will meet on Nov. 6 to discuss an NDA from Merck for Bridion sugammadex to reverse neuromuscular blockade due to muscle relaxants rocuronium or vecuronium. The PDUFA...
BC Week In Review | May 4, 2015
Clinical News

Bridion sugammadex regulatory update

FDA issued a complete response letter to Merck for an NDA for sugammadex to reverse neuromuscular blockade due to muscle relaxants rocuronium or vecuronium. Merck said FDA asked for additional sensitivity analyses regarding the data...
BC Week In Review | Mar 30, 2015
Clinical News

Bridion sugammadex regulatory update

FDA cancelled the March 18 meeting of its Anesthetic and Analgesic Drug Products Advisory Committee to discuss Merck’s sugammadex to reverse neuromuscular blockade due to muscle relaxants rocuronium or vecuronium. The company expects to receive...
Items per page:
1 - 10 of 60